Get the Stockscreener App
45.43
1.11%
0.50
After Hours:
45.43
Supernus Pharmaceuticals Inc stock is traded at $45.43, with a volume of 600.88K.
It is up +1.11% in the last 24 hours and up +22.62% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$44.93
Open:
$44.99
24h Volume:
600.88K
Relative Volume:
0.75
Market Cap:
$2.55B
Revenue:
$651.97M
Net Income/Loss:
$59.71M
P/E Ratio:
42.47
EPS:
1.0696
Net Cash Flow:
$172.03M
1W Performance:
+0.13%
1M Performance:
+22.62%
6M Performance:
+43.54%
1Y Performance:
+29.80%
1-Day Range:
$44.68
$45.50
1-Week Range:
$44.10
$45.94
52-Week Range:
$29.16
$45.94
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
45.43 | 2.50B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
153.20 | 67.75B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.29 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.84 | 43.70B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.48 | 21.51B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
380.47 | 18.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
How sentiment analysis helps forecast Supernus Pharmaceuticals Inc.July 2025 Setups & High Yield Equity Trading Tips - Newser
Analyzing recovery setups for Supernus Pharmaceuticals Inc. investorsFed Meeting & Advanced Technical Analysis Signals - Newser
What makes Supernus Pharmaceuticals Inc. stock price move sharplyJuly 2025 Reactions & Technical Entry and Exit Alerts - Newser
Will earnings trigger a reversal in Supernus Pharmaceuticals Inc.July 2025 Summary & Safe Capital Preservation Plans - Newser
Will Supernus Pharmaceuticals Inc. benefit from seasonalityMarket Sentiment Review & Reliable Entry Point Alerts - khodrobank.com
Real time breakdown of Supernus Pharmaceuticals Inc. stock performanceNew Guidance & Intraday High Probability Alerts - Newser
Risk vs reward if holding onto Supernus Pharmaceuticals Inc.July 2025 Pullbacks & High Conviction Buy Zone Alerts - Newser
Predicting Supernus Pharmaceuticals Inc. trend using moving averagesBond Market & Long-Term Safe Investment Plans - Newser
Custom strategy builders for tracking Supernus Pharmaceuticals Inc.July 2025 Final Week & Technical Pattern Recognition Alerts - Newser
How to build a custom watchlist for Supernus Pharmaceuticals Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - Newser
Sector ETF performance correlation with Supernus Pharmaceuticals Inc.2025 Price Action Summary & AI Driven Price Predictions - Newser
Candlestick signals on Supernus Pharmaceuticals Inc. stock today2025 Technical Patterns & Real-Time Buy Signal Notifications - Newser
Has Supernus Pharmaceuticals Inc. found a price floorMarket Risk Summary & Safe Capital Growth Trade Ideas - Newser
Supernus Pharmaceuticals stock hits 52-week high at $45.85 - Investing.com
Supernus Pharmaceuticals stock hits 52-week high at $45.85 By Investing.com - Investing.com UK
Can Supernus Pharmaceuticals Inc. expand into new marketsMarket Weekly Review & Low Drawdown Investment Strategies - khodrobank.com
EV Market: What are Supernus Pharmaceuticals Inc.’s recent SEC filings showingPortfolio Return Report & Detailed Earnings Play Strategies - khodrobank.com
Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio - Yahoo Finance
Using data filters to optimize entry into Supernus Pharmaceuticals Inc.Earnings Recap Report & Fast Entry Momentum Alerts - Newser
Is Supernus Pharmaceuticals Inc. stock showing strong momentum2025 Biggest Moves & Daily Profit Maximizing Tips - khodrobank.com
What technical models suggest about Supernus Pharmaceuticals Inc.’s comebackPrice Action & Reliable Entry Point Trade Alerts - Newser
Market Outlook: What is the long term forecast for Supernus Pharmaceuticals Inc. stockBear Alert & Safe Entry Momentum Stock Tips - khodrobank.com
What are Supernus Pharmaceuticals Inc.’s earnings expectations2025 Volume Leaders & Daily Technical Stock Forecast Reports - khodrobank.com
Is Supernus Pharmaceuticals Inc. benefiting from interest rate changesJuly 2025 Chart Watch & High Win Rate Trade Tips - khodrobank.com
How to use a screener to detect Supernus Pharmaceuticals Inc. breakoutsEarnings Risk Report & Community Driven Trade Alerts - Newser
Published on: 2025-08-31 13:29:05 - Newser
Recovery Signals Appearing in Supernus Pharmaceuticals Inc. Charts getLinesFromResByArray error: size == 0 - 더경남뉴스
Regression analysis insights on Supernus Pharmaceuticals Inc. performance2025 Winners & Losers & Free Safe Capital Growth Stock Tips - Newser
Historical volatility pattern of Supernus Pharmaceuticals Inc. visualizedJuly 2025 PostEarnings & AI Based Buy/Sell Signal Reports - Newser
Technical analysis overview for Supernus Pharmaceuticals Inc. stockJuly 2025 Trade Ideas & Stock Portfolio Risk Management - Newser
Can Supernus Pharmaceuticals Inc. Regain Momentum After BreakdownJuly 2025 Setups & Smart Allocation Stock Reports - beatles.ru
How institutional ownership impacts Supernus Pharmaceuticals Inc. stock2025 Year in Review & Verified Stock Trade Ideas - Newser
Candlestick Reversal Detected on Supernus Pharmaceuticals Inc.’s ChartJuly 2025 Movers & Weekly Sector Rotation Insights - beatles.ru
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Supernus Pharmaceuticals Inc Stock (SUPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khattar Jack A. | President, CEO |
Aug 27 '25 |
Option Exercise |
12.98 |
17,195 |
223,191 |
1,088,654 |
| Khattar Jack A. | President, CEO |
Aug 28 '25 |
Sale |
45.12 |
24,150 |
1,089,648 |
1,092,633 |
| Khattar Jack A. | President, CEO |
Aug 27 '25 |
Sale |
45.05 |
10,650 |
479,782 |
1,078,004 |
| NEWHALL CHARLES W III | Director |
Aug 27 '25 |
Sale |
45.01 |
3,588 |
161,496 |
129,644 |
3.60%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):